Group items tagged

losartan

evidence that breast cancer chemotherapy can be influenced by anti-hypertensive treatment

Renin catalyses the conversion of AGN to angiotensin I (ATI), which is quickly cleaved by angiotensin converting enzyme (ACE) to form angiotensin II (ATII)

ATII triggers the release of aldosterone from the adrenal glands, which stimulates reabsorption of sodium and water and thereby increases blood volume and blood pressure

ATII also acts on smooth muscle to cause vasoconstriction of the arterioles

ATII promotes the release of antidiuretic hormone from the posterior pituitary gland, which results in water retention and triggers the thirst reflex

ability of non-CSCs to ‘de-differentiate’ into CSCs due to epigenetic or environmental factors, which further increases the complexity of tumour biology and treatment

efficacy of RAS modulators on cancer in both cancer models and cancer patients

A localised (‘paracrine’) RAS mechanism has been identified in many types of cancers, and interruption of the control of the RAS is thought to be the basis for its role in cancer

Components of the RAS are expressed by these CSCs, supporting the hypothesis of the presence of a ‘paracrine RAS’ in regulating these CSCs

Renin is an enzyme normally released by the kidneys in response to falling arterial pressure

a study of GBM demonstrating overexpression of PRR coupled with the observation that inhibition of renin reduces cellular proliferation and promotes apoptosis

PRR has been found to be vital for normal Wnt signalling

A major focus of PRR research is its relationship with Wnt signalling

suggest a crucial role for PRR activation on the proliferation of CSCs, possibly via Wnt/β-catenin signalling, leading to carcinogenesis.

Angiotensin converting enzyme (ACE), also known as CD143, is the endothelial-bound peptidase which physiologically converts ATI to ATII

ACE is crucial in the regulation of blood pressure, angiogenesis and inflammation

results suggest that an overactive ACE promotes cancer growth and progression, and an inhibited or low-activity ACE may have cancer-protective effects

When bound to ATII or ATIII it causes vasoconstriction by stimulating the release of vasopressin, reabsorption of water and sodium by promoting secretion of aldosterone and insulin, fibrosis, cellular growth and migration, pro-inflammation, glucose release from the liver, increased plasma triglyceride concentration, and reduced gluconeogenesis

ATIIR1 is a G-protein-coupled receptor, with downstream signalling involved in vasodilation, hypertrophy and NF-κB activation leading to TNF-α and PAI-1 expression

ATIIR1 has well-documented links with cancer, with one study demonstrating its overexpression in ~20% of breast cancer patients

the effect of RAS dysregulation has been associated with increased VEGF expression and angiogenesis in cancers

In ovarian and cervical cancer, ATIIR1 overexpression has been shown to be an indicator of tumour invasiveness

administration of ATIIR1 blockers (ARBs) have been associated with reduced tumour size, reduction in tumour vascularisation, lower occurrence of metastases, and lower VEGF levels